We developed a quantitative semi high-throughput assay to measure ASE of DAPK1 and applied this new method to test the hypothesis that ASE of DAPK1 is both biologically and clinically significant in CLL. This evidence concerns the gene DAPK1 and B-cell chronic lymphocytic leukemia.